(Q36235489)

12 August 2017

1 reference

title

Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy (English)

1 reference

12 August 2017

anti-retroviral agent

0 references

drug interaction

0 references

author name string

Giovanni Di Perri

1

1 reference

12 August 2017

Diego Aguilar Marucco

2

1 reference

12 August 2017

Alessandra Mondo

3

1 reference

12 August 2017

Daniel Gonzalez de Requena

4

1 reference

12 August 2017

Sabrina Audagnotto

5

1 reference

12 August 2017

Federico Gobbi

6

1 reference

12 August 2017

Stefano Bonora

7

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 September 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

5

1 reference

12 August 2017

821-836

1 reference

Tuberculosis in HIV-infected patients: a comprehensive review.

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

The treatment of tuberculosis in HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Issues in the management of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

The pharmacokinetics of HIV protease inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

The intracellular pharmacology of antiretroviral protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Rifampin and rifabutin drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Indinavir and rifabutin drug interactions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Drug interactions between antiretroviral drugs and comedicated agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Low antituberculosis drug concentrations in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Clinical pharmacokinetics of the antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Immune restoration disease after antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Paradoxical worsening of tuberculosis in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Enfuvirtide: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

21 January 2018

Emerging anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Prospects for new antitubercular drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

Monitoring of long-term toxicities of HIV treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.5.821

21 January 2018

Identifiers

DOI

10.1517/14740338.4.5.821

1 reference

12 August 2017

1 reference